Home>>Signaling Pathways>> Apoptosis>> Other Apoptosis>>SS28

SS28

Catalog No.GC37678

SS28, a SRT501 analog with oral bioavailability, inhibits tubulin polymerization to cause cell cycle arrest at G2/M phase. SS28 results in apoptosis rather than necrosis tubulin.

Products are for research use only. Not for human use. We do not sell to patients.

SS28 Chemical Structure

Cas No.: 141172-08-9

Size Price Stock Qty
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

SS28, a SRT501 analog with oral bioavailability, inhibits tubulin polymerization to cause cell cycle arrest at G2/M phase. SS28 results in apoptosis rather than necrosis tubulin[1]. Tubulin[1].

SS28 (0-20 μM) induces cytotoxicity in different cancer cell lines[1].SS28 treatment (5 μM for A549 and 2 μM for CEM) results in cell cycle arrest at G2/M phase leading to apoptosis upon further incubation[1]. Cell Proliferation Assay[1] Cell Line: CEM, Reh, Nalm6, SUDHL8, Molt4, A549, HeLa 293T cells.

SS28 (15 mg/kg. b.wt.) treatment results in inhibition of tumor cell proliferation[1]. Animal Model: BALB/c mice using EAC cells[1].

[1]. Thomas E, et al. A Novel Resveratrol Based Tubulin Inhibitor Induces Mitotic Arrest and Activates Apoptosis in Cancer Cells. Sci Rep. 2016 Oct 17;6:34653.

Reviews

Review for SS28

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for SS28

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.